IN THE UNITED STATES DISTRICT COURT  FOR THE DISTRICT OF MARYLAND      MARK LANASA, M.D., Ph.D,  *        Plaintiff  *      Civ. No. DLB-22-1399  v.  *        ASTRAZENECA PHARMACEUTICALS *   LP,      *  Defendant.      *      MEMORANDUM OPINION    Mark Lanasa claims his former employer, AstraZeneca Pharmaceuticals LP  (“AstraZeneca”), breached an agreement to give him a bonus under the company’s incentive plan.  ECF 4. He asserts a violation of the Maryland Wage Payment and Collection Law, Md. Code  Ann., Lab. & Empl. § 3-501et seq.(“MWPCL”), breach of contract, and quantum meruit/unjust  enrichment. AstraZeneca has moved to dismiss the complaint for failure to state a claim. ECF 8.  Lanasa has filed an opposition, and AstraZeneca replied. ECF 16, 17. A hearing is not necessary.  Loc. R. 105.6. For the following reasons, the motion to dismiss is granted.  I.  Background  A. Lanasa’s allegations  In deciding the motion to dismiss, the Court accepts the following well-pleaded allegations  as true. Mark Lanasa, M.D., Ph.D., was hired by AstraZeneca in 2017 as Senior Director, Study  Division. ECF 4, ¶ 4. His offer letter, dated May 11, 2017, set out the terms of his employment.  Id.He was offered an initial salary of $300,000 per year.Id.The letter stated that he  will be eligible to participate in the AstraZeneca Incentive Plan (AZIP). Under this plan, your annual incentive target will be 40% of your actual base earnings for the  Case 8:22-cv-01399-DLB Document 20 Filed 03/15/23 Page 1 of 16